272 related articles for article (PubMed ID: 10834270)
1. Nitracrine N-oxides: effects of variations in the nature of the side chain N-oxide on hypoxia-selective cytotoxicity.
Lee HH; Wilson WR; Denny WA
Anticancer Drug Des; 1999 Dec; 14(6):487-97. PubMed ID: 10834270
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide.
Lee HH; Wilson WR; Ferry DM; van Zijl P; Pullen SM; Denny WA
J Med Chem; 1996 Jun; 39(13):2508-17. PubMed ID: 8691448
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide.
Palmer BD; Wilson WR; Anderson RF; Boyd M; Denny WA
J Med Chem; 1996 Jun; 39(13):2518-28. PubMed ID: 8691449
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
Hay MP; Gamage SA; Kovacs MS; Pruijn FB; Anderson RF; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2003 Jan; 46(1):169-82. PubMed ID: 12502371
[TBL] [Abstract][Full Text] [Related]
5. Comparison of aromatic and tertiary amine N-oxides of acridine DNA intercalators as bioreductive drugs. Cytotoxicity, DNA binding, cellular uptake, and metabolism.
Siim BG; Hicks KO; Pullen SM; van Zijl PL; Denny WA; Wilson WR
Biochem Pharmacol; 2000 Oct; 60(7):969-78. PubMed ID: 10974206
[TBL] [Abstract][Full Text] [Related]
6. 5-Nitro-4-(N,N-dimethylaminopropylamino)quinoline (5-nitraquine), a new DNA-affinic hypoxic cell radiosensitizer and bioreductive agent: comparison with nitracrine.
Wilson WR; Siim BG; Denny WA; van Zijl PL; Taylor ML; Chambers DM; Roberts PB
Radiat Res; 1992 Sep; 131(3):257-65. PubMed ID: 1438685
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and anti-cancer activity of 2,6-disubstituted N-methylpiperidine derivatives and their N-oxides.
Henderson ND; Plumb JA; Robins DJ; Workman P
Anticancer Drug Des; 1996 Sep; 11(6):421-38. PubMed ID: 8836108
[TBL] [Abstract][Full Text] [Related]
8. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
[TBL] [Abstract][Full Text] [Related]
9. Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs.
Patterson LH; Craven MR; Fisher GR; Teesdale-Spittle P
Oncol Res; 1994; 6(10-11):533-8. PubMed ID: 7620222
[TBL] [Abstract][Full Text] [Related]
10. Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N.
Wilson WR; Denny WA; Pullen SM; Thompson KM; Li AE; Patterson LH; Lee HH
Br J Cancer Suppl; 1996 Jul; 27():S43-7. PubMed ID: 8763844
[TBL] [Abstract][Full Text] [Related]
11. N-[2-(2-methyl-5-nitroimidazolyl)ethyl]-4-(2-nitroimidazolyl)butanamide (NSC 639862), a bisnitroimidazole with enhanced selectivity as a bioreductive drug.
Moselen JW; Hay MP; Denny WA; Wilson WR
Cancer Res; 1995 Feb; 55(3):574-80. PubMed ID: 7834627
[TBL] [Abstract][Full Text] [Related]
12. New quinoxaline 1,4-di-N-oxides. Part 1: Hypoxia-selective cytotoxins and anticancer agents derived from quinoxaline 1,4-di-N-oxides.
Amin KM; Ismail MM; Noaman E; Soliman DH; Ammar YA
Bioorg Med Chem; 2006 Oct; 14(20):6917-23. PubMed ID: 16843668
[TBL] [Abstract][Full Text] [Related]
13. Novel N-oxide of naphthalimides as prodrug leads against hypoxic solid tumor: synthesis and biological evaluation.
Yin H; Xu Y; Qian X; Li Y; Liu J
Bioorg Med Chem Lett; 2007 Apr; 17(8):2166-70. PubMed ID: 17331719
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-selective antitumor agents. 15. Modification of rate of nitroreduction and extent of lysosomal uptake by polysubstitution of 4-(alkylamino)-5-nitroquinoline bioreductive drugs.
Siim BG; Atwell GJ; Anderson RF; Wardman P; Pullen SM; Wilson WR; Denny WA
J Med Chem; 1997 Apr; 40(9):1381-90. PubMed ID: 9135035
[TBL] [Abstract][Full Text] [Related]
15. DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.
Hay MP; Pruijn FB; Gamage SA; Liyanage HD; Kovacs MS; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2004 Jan; 47(2):475-88. PubMed ID: 14711317
[TBL] [Abstract][Full Text] [Related]
16. Bis-bioreductive agents as hypoxia-selective cytotoxins: nitracrine N-oxide.
Wilson WR; Van Zijl P; Denny WA
Int J Radiat Oncol Biol Phys; 1992; 22(4):693-6. PubMed ID: 1544839
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-selective antitumor agents. 4. Relationships between structure, physicochemical properties, and hypoxia-selective cytotoxicity for nitracrine analogues with varying side chains: the "iminoacridan hypothesis".
Denny WA; Atwell GJ; Anderson RF; Wilson WR
J Med Chem; 1990 May; 33(5):1288-95. PubMed ID: 2329552
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives.
Wilson WR; Thompson LH; Anderson RF; Denny WA
J Med Chem; 1989 Jan; 32(1):31-8. PubMed ID: 2909741
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-selective nitrobenzyloxycarbonyl derivatives of 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazines.
Shyam K; Penketh PG; Shapiro M; Belcourt MF; Loomis RH; Rockwell S; Sartorelli AC
J Med Chem; 1999 Mar; 42(5):941-6. PubMed ID: 10072691
[TBL] [Abstract][Full Text] [Related]
20. Nitroimidazole-based "extruded mustards' designed as reductively activated hypoxia-selective cytotoxins.
Hay MP; Denny WA; Wilson WR
Anticancer Drug Des; 1996 Jul; 11(5):383-402. PubMed ID: 8765531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
